EXPLORE EVIDENCE

Percepta GSC evidence library

Publications and Abstracts

Percepta GSC has been clinically and analytically validated, and has shown utility through clinical utility studies and real world evidence. 

AABIP 2019 Conference
Percepta GSC can down-classify the risk of primary lung cancer to low with a 91% NPV to help avoid additional invasive procedures or up-classify the risk to high with a 65% PPV to inform next intervention steps.
CHEST 2021 Conference
Dr. Abhijit Raval reviews data where he and his colleagues sought to identify the frequency with which Percepta GSC helps to reclassify malignancy risk in intermediate risk nodules to guide further decision-making.
Preview thumbnail for publication
American Thoracic Society Virtual Meeting
Percepta GSC improves the diagnostic utility of bronchoscopy with a combined sensitivity of 96%. Hear Presentation.
Preview thumbnail for publication
BMC Pulmonary Medicine
Percepta GSC increased the number of surgical and other ablative therapies recommended when patients were re-classified from high to very high-risk of lung cancer with a higher confidence in the recommended next step. By up-classifying nodules from high to very high ROM, Percepta GSC will improve the likelihood and timeliness of appropriate therapies and assist clinicians more effectively manage patients to improve patient outcomes.
Preview thumbnail for publication
CHEST Journal
The down-classification of nodule malignancy risk with Percepta GSC decreased additional invasive procedures without a delay in time to diagnosis among those with lung cancer.
BMC Medical Genomics
The Percepta GSC demonstrated diagnostic accuracy in both down- and up-classification of cancer risk, providing physicians actionable information for many patients with inconclusive bronchoscopy.
BMC Cancer
Percepta GSC for risk stratification of suspicious lung nodules can be performed with high confidence in the clinical setting.

Hear from peers

Discover what key opinion leaders are saying about Percepta GSC in case studies, testimonials or on-demand presentations.